Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
$25 Million Gift to Penn Medicine and Children's Hospital of Philadelphia Establishes Center for Epilepsy and Neurodevelopmental Disorders
A $25 million gift from an anonymous donor to Penn Medicine and Children’s Hospital of […]
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
Rocket Pharmaceuticals, a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic […]
Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest
Accenture has acquired Bionest, a strategy and consulting firm dedicated to addressing complex strategic decisions […]
AviadoBio Announces Appointment of Jeff Goater as Chair of the Board of Directors
AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines […]
ProtaGene Appoints New Scientific and Commercial Leadership to Support Evolving Needs of Biologic and Cell & Gene Therapy Innovators
ProtaGene, a leading global contract research organization focused on advanced analytics in biologics and cell […]
Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear
Sensorion, a pioneering clinical-stage biotechnology company that specializes in the development of novel therapies to […]
Immusoft Awarded $8M in Funding from the California Institute for Regenerative Medicine (CIRM) for MPS I Clinical Program
Immusoft of CA, a wholly owned subsidiary of Immusoft, a clinical-stage cell therapy company dedicated […]
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy
REGENXBIO today announced that the Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 for the treatment […]
FDA Accepts GMP Plasmid DMF of OBiO Technology
OBiO Technology, a gene and cell therapy-focused contract research organization (CRO) and contract development and […]
Gensaic Receives Funding From the CF Foundation to Develop a Gene Therapy for People With Cystic Fibrosis
Gensaic, a company that seeks to reimagine gene therapy, has announced that it has received […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more